|
BP13956
|
JIB-04
|
|
|
|
|
JIB-04 is a pan-selective Jumonji histone demethylase inhibitor.
|
|
BP13955
|
JGB1741
|
|
|
|
|
JGB1741 is a potent and selective inhibitor of SIRT1 with an IC50 of 15 μM. JGB1741 modulates Bax/Bcl2 ratio, cytochrome c release and PARP cleavage and increases the acetylated p53 levels leading to p53-mediated apoptosis. JGB1741 can be used in studies about breast cancer.
|
|
BP13954
|
JANEX-1
|
|
|
|
|
Janex-1 is a cell-permeable, reversible, effective, ATP-competitive, and selective inhibitor of JAK3 (IC50: 78 μM); little inhibitory against JAK1/2, or Zap/Syk or SRC tyrosine kinases.
|
|
BP13953
|
JAK1-IN-7
|
|
|
|
|
JAK1-IN-7 is a Janus-associated kinase 1 (JAK1) inhibitor, has an anti-inflammatory effect.
|
|
BP13952
|
JAK 3 inhibitor IV
|
|
|
|
|
JAK 3 inhibitor IV is a JAK1/3 inhibitor with pIC50 of 4.4/7.1, almost no activity to JAK2 and modestly potent to EGFR; also found to be sensitive to transglutaminase.
|
|
BP13951
|
J-147
|
|
|
|
|
J147 is an experimental drug with reported effects against both Alzheimer's disease and ageing in mouse models of accelerated aging. It is a curcumin derivative and a potent neurogenic and neuroprotective drug candidate initially developed for the treatment of neurodegenerative conditions associated with aging that impacts many pathways implicated in the pathogenesis of diabetic neuropathy.
|
|
BP13950
|
Ivangustin
|
|
|
|
|
Ivangustin exhibits remarkable cytotoxicity against HEp2, SGC-7901 and HCT116 human cancer cell lines.
|
|
BP13949
|
ITSA-1
|
|
|
|
|
ITSA-1 is membrane permeable and specifically suppresses TSA inhibition of HDAC (histone deacetylase), but shows no activity towards other HDAC inhibitors.
|
|
BP13948
|
Ruboxistaurin hydrochloride
|
|
|
|
|
Isozyme-selective inhibitor of protein kinase C (PKC); competitively and reversibly inhibits PKCβI and PKCβII (IC50 values are 4.7 and 5.9 nM respectively). Selective for PKCβ over other PKC isozymes (IC50values are 0.052, 0.25, 0.30, 0.36, 0.60 and >100 μM for PKCη, -δ, -γ, -α, -ε and -ζ respectively). Exhibits selectivity for PKC over other ATP-dependent kinases, including protein kinase A, casein kinase and src).
|
|
BP13947
|
Isomaltotriose
|
|
|
|
|
Isomaltotriose is a sugar from enzymic hydrolyzates of the dextran from Leuconostoc mesenteroides NRRL B-512.
|
|
BP13946
|
Isojacareubin
|
|
|
|
|
Isojacareubin displays potent activity against H. pylori HP40 clinical isolate with MIC 23.9 uM, which is approximately two times greater than that of the standard drug amoxicillin. Isojacareubin is a potent inhibitor of protein kinase C (PKC), suppresses hepatocellular carcinoma metastasis and induces apoptosis in vitro and in vivo, thus, it as a promising lead compound for the development of new antihepatoma agents.
|
|
BP13945
|
Iso-H7 dihydrochloride
|
|
|
|
|
Iso-H7 dihydrochloride is a less potent inhibitor of phosphokinase C than H-7.
|
|
BP13944
|
Isoferulic acid
|
|
|
|
|
Isoferulic acid is an effective natural antioxidant in both lipid and aqueous media, it may be a new promising anti-glycation agent for the prevention of diabetic complications via inhibition of advanced glycation end products (AGEs) formation and oxidation-dependent protein damage. Isoferulic acid is a novel and potent inhibitor of murine IL-8 production, it also has inhibitory effect on mushroom tyrosinase.
|
|
BP13943
|
IOX4
|
|
|
|
|
IOX4 is a potent PHD2 inhibitor (IC50 = 1.6 nM)
|
|
BP13942
|
IOX2
|
|
|
|
|
IOX2 is a selective inhibitor of the Hypoxia Inducible Factor (HIF) Prolyl-Hydroxylases (PHD); active in cells with the IC50 value of 21 nM for PHD2/ELGN-1 and no inhibition at FIH (20uM).
|
|
BP13941
|
IOX1
|
|
|
|
|
IOX1 is the most effective broad-spectrum 2OG oxygenases(including the JmjC demethylases) inhibitor. The IC50 of IOX1 for KDM4A, KDM3A, is 0.6 and 0.1 uM, respectively.
|
|
BP13940
|
3-Aminobenzamide
|
|
|
|
|
INO-1001 is an effective inhibitor of PARP (IC50<50 nM in CHO cells) and a mediator of oxidant-induced myocyte dysfunction during reperfusion.
|
|
BP13939
|
Iniparib
|
|
|
|
|
Iniparib (BSI-201), a PARP1 inhibitor, exhibits potency in triple-negative breast Y (TNBC).
|
|
BP13938
|
Methyl L-histidinate dihydrochloride
|
|
|
|
|
Inhibition of histidine decarboxylase in Sprague-Dawley rat stomach assessed as decrease in 14CO2 production with activty value of 1.8 μM
|
|
BP13623
|
Ingenol
|
|
|
|
|
Ingenol mebutate is an effective treatment for actinic keratosis. Formulating novel derivatives from Ingenol esters may be an innovative approach to develop new lead compounds to reactivate latent HIV. Ingenol is a weak PKC activator and possesses important anticancer activity.
|
